2010
Antiretroviral medication adherence and class-specific resistance in a large prospective clinical trial
Gardner EM, Hullsiek KH, Telzak EE, Sharma S, Peng G, Burman WJ, MacArthur RD, Chesney M, Friedland G, Mannheimer SB. Antiretroviral medication adherence and class-specific resistance in a large prospective clinical trial. AIDS 2010, 24: 395-403. PMID: 20099399, PMCID: PMC2886717, DOI: 10.1097/qad.0b013e328335cd8a.Peer-Reviewed Original ResearchConceptsInitial virological failureCumulative adherenceVirological failureMedian timeNucleoside reverse transcriptase inhibitor resistanceProspective clinical trial dataInhibitor strategiesLarge prospective clinical trialsReverse transcriptase inhibitor resistanceInhibitor resistanceAntiretroviral-naive participantsProspective clinical trialsCox regression analysisTranscriptase inhibitor resistanceAntiretroviral medication adherenceProtease inhibitor resistanceClinical trial dataProtease inhibitorsMedication resistanceAntiretroviral therapyHIV RNANNRTI resistanceMedication adherenceClinical trialsGenotypic resistance
2008
A randomized comparison of two instruments for measuring self-reported antiretroviral adherence
Mannheimer S, Thackeray L, Hullsiek K, Chesney M, Gardner E, Wu A, Telzak E, Lawrence J, Baxter J, Friedland G, Aids F. A randomized comparison of two instruments for measuring self-reported antiretroviral adherence. AIDS Care 2008, 20: 161-169. PMID: 18293124, DOI: 10.1080/09540120701534699.Peer-Reviewed Original ResearchConceptsSelf-reported adherenceImmunologic outcomesAntiretroviral adherenceStudy visitRecall instrumentSelf-reported antiretroviral adherenceCD4 cells/HIV resistance mutationsMultidrug-resistant HIVSelf-report instrumentVirologic failureAntiretroviral medicationsHIV diseaseMonth 12Randomized comparisonClinical trialsTreatment strategiesAdherence levelsResistance mutationsAdherenceCells/VisitsTrialsDaysMedian
2006
Sustained Benefit From a Long-Term Antiretroviral Adherence Intervention
Mannheimer SB, Morse E, Matts JP, Andrews L, Child C, Schmetter B, Friedland GH. Sustained Benefit From a Long-Term Antiretroviral Adherence Intervention. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2006, 43: s41-s47. PMID: 17091022, DOI: 10.1097/01.qai.0000245887.58886.ac.Peer-Reviewed Original ResearchConceptsAdherence supportAdherence interventionsClinical trialsMedian baseline CD4 countLong-term medication adherenceLarge randomized clinical trialsMM participantsAntiretroviral Adherence InterventionARV-naive individualsBaseline CD4 countFirst virologic failureIntervention clinical trialsRandomized clinical trialsMedication managersCD4 countVirologic failureVirologic outcomesCD4 cellsARV therapyHIV outcomesMedication adherenceMM subgroupsMM groupCluster randomizationCells/Clinician-Delivered Intervention During Routine Clinical Care Reduces Unprotected Sexual Behavior Among HIV-Infected Patients
Fisher JD, Fisher WA, Cornman DH, Amico RK, Bryan A, Friedland GH. Clinician-Delivered Intervention During Routine Clinical Care Reduces Unprotected Sexual Behavior Among HIV-Infected Patients. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2006, 41: 44-52. PMID: 16340472, DOI: 10.1097/01.qai.0000192000.15777.5c.Peer-Reviewed Original ResearchConceptsCare control armUnprotected sexual behaviorInsertive oral sexHIV clinical careRoutine clinical careClinical careControl armAnal intercourseClinician-delivered interventionUnprotected sexSexual behaviorRoutine HIV clinical careOral sexLarge HIV clinicProspective clinical trialsIntervention arm participantsHIV prevention interventionsClinical care providersClient-centered interventionsHIV clinicArm participantsIntervention armClinical trialsPrevention interventionsCare providers
2005
Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence
Mannheimer S, Matts J, Telzak E, Chesney M, Child C, Wu A, Friedland G, Aids F. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care 2005, 17: 10-22. PMID: 15832830, DOI: 10.1080/09540120412331305098.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyART adherenceQOL scoresQuality of lifeTerry Beirn Community ProgramsNewer ART regimensSummary QoL scoresCells/mm3Mean QOL scoreAntiretroviral clinical trialsHigher QoL scoresBaseline CD4ART regimensART-naïveHIV populationMean agePoor adherenceSF-12Clinical trialsImproved QoLClinical researchQoLAdherenceMonthsHIV
2002
The Consistency of Adherence to Antiretroviral Therapy Predicts Biologic Outcomes for Human Immunodeficiency Virus—Infected Persons in Clinical Trials
Mannheimer S, Friedland G, Matts J, Child C, Chesney M, AIDS T. The Consistency of Adherence to Antiretroviral Therapy Predicts Biologic Outcomes for Human Immunodeficiency Virus—Infected Persons in Clinical Trials. Clinical Infectious Diseases 2002, 34: 1115-1121. PMID: 11915001, DOI: 10.1086/339074.Peer-Reviewed Original ResearchConceptsHIV RNA levelsHuman immunodeficiency virusImmunodeficiency virusClinical trialsRNA levelsPlasma HIV RNA levelsBiologic outcomesConsistency of adherenceCopies/mLMulticenter clinical trialAntiretroviral therapyCD4 countMonth 12Nonwhite racePoor adherenceAdherence levelsAdherence patternsOlder ageGood adherenceAdherenceCells/TrialsVisitsOutcomesParticipants
1999
Recruitment in AIDS Clinical Trials: Investigation of Sociodemographic and Psychosocial Factors Affecting Participation in Clinical Research
Ethier K, Rodriguez M, Fox-Tierney R, Martin C, Friedland G, Ickovics J. Recruitment in AIDS Clinical Trials: Investigation of Sociodemographic and Psychosocial Factors Affecting Participation in Clinical Research. AIDS And Behavior 1999, 3: 219-230. DOI: 10.1023/a:1025456527845.Peer-Reviewed Original ResearchTrial participantsIDU historyClinical trialsAIDS clinical trialsGroup of HIVTrial regimenMedical therapyPsychosocial factorsHIV therapeuticsClinical researchTrial resultsTrialsBehavioral factorsHIVSociodemographic dimensionsPrimary objectiveParticipantsNonparticipantsRegimenPatientsTherapyMSMSociodemographicsRecruitment
1996
Stavudine (d4T, Zerit®)
Friedland G, Dunkle L, Cross A. Stavudine (d4T, Zerit®). Advances In Experimental Medicine And Biology 1996, 394: 271-277. PMID: 8815691, DOI: 10.1007/978-1-4757-9209-6_24.Peer-Reviewed Original ResearchConceptsAdvanced HIV-1 infectionEffects of stavudinePrior zidovudine therapyHIV-1 infectionImmunologic deteriorationAcceptable toxicityZidovudine therapyHIV diseaseClinical benefitSuch therapySurrogate markerClinical trialsDrug AdministrationStavudineTherapyBeneficial effectsU.S. FoodPatientsInfectionDiseaseAdministrationProgressionTrials